Background-Ventilatory efficiency (VE/VCO 2 slope) and peak oxygen consumption (VO) provide robust prognostic information in patients with heart failure undergoing cardiopulmonary exercise testing (CPX). The purpose of this study is to assess the change in prognostic characteristics of CPX at different time intervals. Methods and Results-Seven hundred ninety-one subjects (74% male, mean age: 60.7Ϯ12.9 years, ejection fraction: 34.6Ϯ15.0%, ischemic etiology: 51%) underwent CPX and were tracked for major cardiac events over a 4-year period. All event-free subjects were tracked for at least 3 years. Mean VE/VCO 2 slope and peak VO 2 were 35.0Ϯ10.0 and 16.0Ϯ6.4 mL O 2 ⅐ kg Ϫ1 ⅐ min Ϫ1 , respectively. There were a total of 263 major cardiac events (199 deaths, 45 transplants, and 19 left ventricular assist device implantations). Both continuous and dichotomous expressions of the VE/VCO 2 slope and peak VO 2 were prognostically significant up to 18 months post-CPX. Continuous and dichotomous expressions of the VE/VCO 2 slope remained prognostically significant up to 36 months post-CPX, whereas peak VO 2 was not predictive during the third and fourth year of follow-up. In a multivariate analysis, the VE/VCO 2 slope was consistently the superior prognostic marker, whereas peak VO 2 added predictive value and was retained in the regression up to 18 months post-CPX. Conclusions-These results indicate that commonly assessed CPX variables retain prognostic value for at least 2 years.
C ardiopulmonary exercise testing (CPX) is a wellaccepted evaluation technique in patients with heart failure (HF), as indicated by position stands put forth by American 1 and European 2 organizations. The premise for the strong level of support for the application of CPX in this chronic disease population is the robust body of scientific evidence, now spanning Ͼ25 years, consistently demonstrating the prognostic value provided by variables attained from ventilatory expired gas analysis. 3 From CPX, the minute ventilation/carbon dioxide production (VE/VCO 2 ) slope and peak oxygen consumption (VO) are the most frequently assessed variables for prognostic purposes and, although the former seems to provide superior predictive information, multivariate modeling including both measures is recommended. 3 
Clinical Perspective on p 411
From the entire HF population, it seems that those patients being actively considered for heart transplantation are most often referred for CPX to assist in determining whose prognosis is least favorable and therefore in the greatest need of surgical intervention. Although clinicians afford a high level of predictive credibility to information obtained from CPX, little consideration is given to the length of time the data provide valid insight into which patients are at greatest risk for adverse events. Our group has attempted to address this issue in the past, finding the prognostic strength of both the VE/VCO 2 slope and peak VO 2 is diminished Ͼ1 year after CPX. 4 This initial investigation was performed in a relatively small cohort (nϭ258) with a limited amount of hard end points (45 cardiac-related deaths).
Although this initial investigation indicated that there was a finite period of time that CPX data should be considered for prognostic purposes in patients with HF, additional analysis is needed. Given the fluid nature of this chronic disease, from asymptomatic left ventricular dysfunction to refractory HF, the prognostic applications of CPX should not be considered indefinite. However, the optimal window for applying CPX data in a prognostic context has not been well defined. Clarifying this window would have implications for the frequency with which patients with HF should be referred for CPX and would further optimize the application of this procedure. The purpose of this investigation was to further define an optimal prognostic window for CPX responses in patients with HF.
Methods
This study is a multicenter analysis including patients with HF from the exercise testing laboratories at San Paolo Hospital, Milan, Italy; Wake Forest University Baptist Medical Center, Winston-Salem, NC; LeBauer Cardiovascular Research Foundation, Greensboro, NC; VA Palo Alto Health Care System, Palo Alto, Calif; and Virginia Commonwealth University, Richmond, Va. A total of 791 patients with chronic HF were included. Inclusion criteria were a diagnosis of HF 5 and evidence of left ventricular dysfunction by 2-dimensional echocardiography obtained within 1 month of data collection. All subjects completed a written informed consent and institutional review board approval was obtained at each institution.
CPX Procedures
Symptom-limited CPX was performed on all subjects and pharmacological therapy was maintained during exercise testing. Conservative ramping protocols were used at all centers, and ventilatory expired gas analysis was performed using a metabolic cart (Medgraphics CPX-D and Ultima, Minneapolis, Minn, Sensormedics Vmax29, Yorba Linda, Calif, or Parvomedics TrueOne 2400, Sandy, Utah). A treadmill and lower extremity ergometer were used as the exercise mode in 69% and 31% of the tests, respectively. Before each test, the equipment was calibrated in standard fashion using reference gases. Minute ventilation (VE), oxygen uptake (VO), and carbon dioxide output (VCO 2 ) were acquired breath-by-breath and averaged over 10-second intervals. Peak VO 2 and peak respiratory exchange ratio (RER) were expressed as the highest 10-second averaged sample obtained during the last 20 seconds of testing. VE and VCO 2 values, acquired from the initiation of exercise to peak, were input into spreadsheet software (Microsoft Excel, Microsoft Corp., Bellevue, Wash) to calculate the VE/VCO 2 slope using least squares linear regression (yϭmxϩb, mϭslope). Previous studies have shown that this method of calculating the VE/VCO 2 slope to be prognostically optimal. 3
End Points
In the overall cohort, subjects were followed up for major cardiac events (mortality, left ventricular device implantation, urgent heart transplantation) via medical chart review. Subjects were followed up by the HF programs at their respective institution providing a high likelihood that all events were captured. External means of tracking events, such as the Social Security Death Index, were not used in this study. Any death with a cardiac-related discharge diagnosis was considered an event. Subjects in the overall group who did not have a major cardiac event were tracked for a minimum of 3 years.
Statistical Analysis
Statistical software packages (SPSS 17.0, Chicago, Ill and StudySize 2.0, Vastra Frolunda, Sweden) were used to perform all analyses. Continuous data are reported as meanϮstandard deviation. One-way ANOVA was used to assess differences in continuous variables between subjects who remained event free or had a major cardiac event at 6-month intervals for the overall group tracked for 3 years. Post hoc analysis was performed by Tukey's honestly significant difference test. Chi-square analysis assessed distribution differences of categorical data among groups. Independent t tests were used to assess differences in CPX variables between subgroups of subjects who remained event free for 4 years or had a major cardiac event either between 36 and 42 or between 42 and 48 months. In subjects experiencing a major cardiac event, Pearson product-moment correlation analysis was used to assess the relationship between both peak VO and the VE/VCO 2 slope and time to event. A series of Cox proportional hazard models were performed to assess the prognostic value of peak VO and the VE/VCO 2 slope, both as continuous and dichotomous expressions (VE/VCO 2 slope: Ͻ36/Ն36; peak VO: Ͻ10/Ն10 mL ⅐ kg Ϫ1 ⅐ min Ϫ1 ), during the 4-year tracking period. The first was a traditional time-to-event analysis with the date of CPX serving as the baseline time point. Subsequent proportional hazard models began follow-up time at succeeding 6-month intervals post-CPX. Subjects having an event in the preceding 6 months were removed from the next analysis. Dichotomous thresholds for both CPX variables were based on previous investigations demonstrating their prognostic significance. 3 By using all cardiac events, a post hoc power analysis was conducted for both CPX variables (continuous expressions) for all Cox proportional hazard models. Derived hazard ratios and total number of cardiac events were used to calculate power. Kaplan-Meier analysis assessed event-free survival of the VE/VCO 2 slope and peak VO according to the 4 level Ventilatory 6 and Weber 7 classification systems, respectively. Multivariate Cox regression (forward stepwise method; entry and removal value 0.05 and 0.10, respectively) assessed the combined prognostic value of peak VO and the VE/VCO 2 slope as continuous expressions. Multivariate survival analysis was used to assess the combined prognostic value of all variables listed in Table 1 in addition to the aforementioned CPX variables. For this latter analysis, major cardiac events were considered for the first 3 years after CPX. Finally, univariate Cox regression assessed the prognostic value of CPX at each of the 5 laboratories included in the analysis and based on mode of exercise as well as a peak RER threshold of Ͻ1.00/Ն1.00. A P value of Ͻ0.05 was considered statistically significant for all tests.
Results
The characteristics of the clinical and cardiac events of the 791 subjects included in this analysis are listed in Table 1 . Five hundred sixty subjects remained event free for 3 years, whereas the remaining 231 subjects experienced a major cardiac event during that time period (annual event rate: 9.9%). None of the subjects who remained event free for 3 years post-CPX was lost to follow-up over that time period. One hundred thirteen subjects were lost to follow-up during the fourth year of tracking. Over the first 3 years of tracking, 168 events were cardiac-related mortality (annual mortality rate: 7.3%). Several significant differences existed according to event status. Of note, New York Heart Association class was significantly lower and the left ventricular ejection fraction was significantly higher in subjects who were event free compared with those subjects having a major cardiac event during the first 2 years after CPX. Both variables were comparable between subjects who were event free and those having a major cardiac event during the third year after CPX.
CPX characteristics are listed in Table 2 . Peak RER was comparable among groups, indicating similar effort. Peak VO 2 was significantly higher in subjects who remained event free compared with those who had a major cardiac event during the first 2 years after CPX ( Figure 1 ). The VE/VCO 2 slope was significantly lower in subjects who remained event free compared with those having a major cardiac event during the first 2 1 ⁄2 years after CPX. Moreover, the VE/VCO 2 slope was significantly higher in subjects having a major cardiac event in the first 6 months compared with subjects having a major cardiac event from 6 to 12, 12 to 18, and 30 to 36 months ( Figure 2 ).
Four hundred ninety-nine subjects were tracked and remained event free for 42 months, whereas 13 had a major cardiac event between 36 and 42 months. The difference in peak VO 2 (no event: 17.5Ϯ6.6 versus event: 17.8Ϯ8.7 mL ⅐ kg Ϫ1 ⅐ min Ϫ1 , Pϭ0.98) and peak RER (no event:
1.09Ϯ0.17 versus event: 1.12Ϯ0.18, Pϭ0.56) was not significantly different, whereas the VE/VCO 2 slope (no event: 32.0Ϯ7.7 versus event: 38.0Ϯ17.8, Pϭ0.008) was significantly higher in subjects having a cardiac event. In addition, 428 subjects were tracked and remained event free for 48 months, whereas 19 died because of cardiac event between 42 and 48 months. During the last 6 months of the fourth year, the differences in peak VO 2 (no event: 17.7Ϯ6.6 versus event: 15.7Ϯ6.4 mL ⅐ kg Ϫ1 ⅐ min Ϫ1 , Pϭ0.26), peak RER (no event: 1.09Ϯ0.17 versus event: 1.12Ϯ0.19, Pϭ0.48), and the VE/ VCO 2 slope (no event: 31.9Ϯ7.7 versus event: 35.3Ϯ10.1, Pϭ0.06) were not significant according to event status.
In the subjects experiencing a major cardiac event over the 4-year tracking period (nϭ263), Pearson product-moment correlation revealed that the VE/VCO 2 slope (rϭϪ0.24, PϽ0.001) and peak VO (rϭ0.32, PϽ0.001) were both significantly correlated with time to event.
CPX variables of interest were significant predictors (PϽ0.05) of adverse events irrespective of: CPX laboratory, exercise mode, or a peak threshold of Ͻ1.00/Ն1.00. In each instance, the VE/VCO 2 slope was the superior prognostic marker. Kaplan-Meier analysis revealed the 4-level Weber 7 (Figure 3 ) and Ventilatory 6 ( Figure 4 ) classification systems clearly delineated risk over the 3 years after CPX.
Cox proportional hazards models are listed in Table 3 . Both continuous and dichotomous expressions of the VE/ VCO 2 slope were significant predictors of major cardiac events and cardiac mortality at each 6-month interval for the *Peak VO 2 : no-event group greater than 0-to 6-, 6-to 12-, 12-to 18-, and 18-to 24-month event groups (PϽ0.001). †The VE/VCO 2 slope: no-event group less than 0-to 6-, 6-to 12-, 12-to 18-, 18-to 24-, and 24-to 30-month event groups (PϽ0.001). ‡The VE/VCO 2 slope was greater for the 0-to 6-month group than for the 6-to 12-, 12-to 18-, and 30-to 36-month event groups (PϽ0.05).
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first 3 1 ⁄2 years after CPX. Power calculations for survival analysis using the VE/VCO 2 slope remained above 90% up to 30 months post-CPX and dropped to 79% and 61% for the 36and 42-month post-CPX analyses, respectively. The continuous expression of peak VO 2 was a significant predictor of major cardiac events and cardiac mortality up to and including the 24-month post-CPX hazards model, whereas dichotomous expression was no longer significant after 12 months post-CPX. Neither expression of peak VO 2 identified subjects at increased risk from 30 months post-CPX to the end of tracking. When considering peak VO 2 as the prognostic variable, power was Ͼ90% up to 18 months post-CPX, dropped to 64% 24 months CPX, and declined to Ͻ50% thereafter. Multivariate Cox regression results revealed that the VE/VCO 2 slope and peak VO 2 were both retained in the model when considering all events and up to 18 months post-CPX. The VE/VCO 2 slope was the superior prognostic marker in each instance, whereas peak VO 2 added predictive value (residual 2 : Ն4.2, PϽ0.05). The VE/VCO 2 slope was the only variable retained in the regression from 24 to 36 months post-CPX. Neither the VE/VCO 2 slope nor peak VO was entered into the multivariate regression at 42 months post-CPX. When combining these CPX variables with all variables listed in Table 1 , the VE/VCO 2 slope remained the strongest prognostic marker ( 2 : 197.6, PϽ0.001). Left ventricular ejection fraction, New York Heart Association class, age and peak VO added prognostic value and were retained (residual 2 Ն5.0, PϽ0.05).
Discussion
The prognostic power of CPX in HF is firmly supported by a wealth of original research. 6, 8, 9 Peak VO 2 and the VE/VCO 2 slope are the most thoroughly investigated variables and are therefore afforded a high degree of clinical recognition and acceptance. 10 This is particularly true for peak VO 2 , although evidence now supports the prognostic superiority of the VE/VCO 2 slope in the HF population, 3 a finding confirmed in this investigation. Historically, prognostic analyses have tracked events after CPX without considering the potential influence time past the initial assessment has on the prognostic ability of peak VO 2 and the VE/VCO 2 slope. Our group addressed this previously, demonstrating the ability of both CPX variables to accurately predict that an increased risk for cardiac mortality and hospitalization was substantially higher within the first year of tracking compared with a longer time frame. 4 This initial analysis included a relatively small cohort (Ͻ300) and small number of events (Ͻ45 deaths, 19 within the first year and 26 over the next 5 years), limiting our ability to perform a more detailed analysis on the effect time post-CPX has on prognostic significance. This investigation attempted to rectify the limitations of our initial analysis and, to our knowledge, is the first one addressing this issue in a detailed manner.
HF is a dynamic condition in which clinical status has the potential to markedly deteriorate over a short time period. It is estimated that 80% of men and 70% of women diagnosed with HF younger than 65 die within 8 years of their diagnosis. 11 It is therefore not surprising that the prognostic value of CPX may not be maintained indefinitely because disease severity will worsen in a majority of these patients in Ͻ10 years. Importantly, peak VO 2 may lose its prognostic value in patients with HF 2 years post-CPX. The VE/VCO 2 slope seems to retain prognostic value for 3 1 ⁄2 years after CPX. In the latter half of the fourth year of tracking, the VE/VCO 2 slope also seems to begin to lose prognostic value. These observations suggest the following: (1) when peak VO 2 and the VE/VCO 2 slope are assessed from a prognostic perspective without consideration of time post-CPX, both are highly prognostic, which is consistent with the previous research 3 ; (2) the prognostic strength of peak VO 2 and the VE/VCO 2 slope may depend on time post-CPX. In combination, peak VO 2 and the VE/VCO 2 slope can be considered for up to 2 years after CPX with a high degree of confidence. The VE/VCO 2 slope may continue to provide prognostic insight into the fourth year after CPX, although its ability to predict risk for adverse events diminishes after 42 months; (3) neither peak VO 2 nor the VE/VCO 2 slope may provide reliable prognostic information during the latter half of the fourth year post-CPX. Although the analysis was not extended into the fifth year after CPX, it is reasonable to hypothesize that the trends of diminished predictive value in the fourth year would continue. However, it should be noted that statistical power began to diminish for the VE/VCO 2 slope during the fourth year of tracking. The results of this study during this time period should therefore be viewed as compelling but in need of future studies to address this issue. Even so, attaining a cohort with enough events in a short time interval to demonstrate these CPX variables is not prognostic after an extended period, and generating a power of at least 80% may be challenging. In addition, the VE/VCO 2 slope maintained prognostic significance for a longer period of time despite the lower event rate into the fourth year. This indicates the lack of prognostic significance for peak VO 2 during this period does portend a potentially important clinical message.
In 62 patients with HF, Florea et al 12 performed 2 CPX evaluations that were at least 4 months apart (mean: 19 months). In the 22 subjects having a major cardiac event, there was a significant reduction in peak VO 2 from the first to second test (18.3 versus 13.9 mL ⅐ kg Ϫ1 ⅐ min Ϫ1 , PϽ0.05), whereas there was no change in subjects who were event free (18.1 versus 20.8 mL ⅐ kg Ϫ1 ⅐ min Ϫ1 ). The difference in peak VO between groups according to event status was not significant during the baseline CPX but differed at the follow-up evaluation (PϽ0.001). The VE/VCO 2 slope increased in subjects having a major cardiac event in this analysis (44.4 versus 50.0) but did not reach statistical significance. The difference in the VE/VCO 2 slope in event-free subjects was more stable between the 2 tests (34.3 versus 35.9) and was significantly lower compared with the group having an adverse event at both the baseline and follow-up tests (PϽ0.001). This previous investigation underscores the fact that CPX responses vary with time and tend to worsen among subjects who subsequently experience an adverse event. This is particularly true for peak VO, which was significantly reduced at follow-up in subjects having an adverse event. The VE/VCO 2 slope seems to be more stable among subjects eventually having an adverse event, exhibiting a significantly higher value at both baseline and follow-up. This stability also seems to be the case for subjects who were event free, where the VE/VCO 2 slope was significantly lower and comparable between baseline and follow-up assessments. The ability of the latter CPX variable to reflect longitudinal disease severity with greater stability during a cross-sectional analysis may be a primary reason for its prognostic superiority in comparison with peak VO. 3 Even so, the prognostic window for the VE/VCO 2 slope after CPX is not indefinite, and subjects initially presenting with a more favorable response will eventually have a higher incidence of adverse events. This is reflected by the statistically significant, albeit weak, correlation between CPX variables and time to event in this study (ie, CPX response improves in subjects having an adverse event at a longer time point from the assessment).
Numerous scientific statements from respected national and international organizations support the use of CPX for prognostic purposes in patients with HF. 1, [13] [14] [15] Moreover, the American Heart Association guidelines for the diagnosis and management of patients with HF recommend the use of CPX to identify high-risk individuals being considered for heart transplantation or other advanced therapies. 16 However, none of these documents address the length of time CPX data maintain prognostic value, an important consideration given the fluid nature of HF etiology and disease progression. Given the results of this investigation, we propose the following: (1) as a conservative estimate, the current results support the prognostic utility of peak VO 2 and the VE/VCO 2 slope for up to 2 years after the exercise assessment; (2) these variables should be assessed in combination over this time period, with progressively higher VE/VCO 2 slope values in combination with progressively lower peak VO 2 values (VC-IV and Weber D), portending the greatest risk for major cardiac events; (3) irrespective of the time frame, subjects initially presenting with a poor CPX response should be considered at high risk for adverse events and monitored accordingly; (4) repeating the CPX every 2 years in patients with HF who initially have a peak VO 2 and VE/VCO 2 slope that places them in the intermediate (Weber B/C and VC-II/III) risk categories is warranted; and (5) patients who are in Weber A and VC-I classes on initial CPX tend to remain at extremely low risk for a longer period. Repeating a CPX every 3 to 4 years may therefore be acceptable in this latter category.
Although the overall number of subjects and events in this investigation is relatively large for this area of study, removing preceding events at 6-month intervals diminishes the ability to perform extensive multivariate analyses. Ten events per predictor variable is a minimal recommended threshold for survival analyses. 17 This threshold was surpassed in all of the univariate analyses and either met or surpassed it for the multivariate analyses during the first 3 1 ⁄2 years after CPX. Even so, statistical power diminished during the third and fourth year of tracking, limiting the strength of conclusions that can be drawn from this portion of the analysis. Moreover, other variables included in standardized prognostic models, such as the Seattle Heart Failure model, 18 were not available in this data set. However, although these variables are certainly valuable, previous investigations have demonstrated that CPX variables, particularly the VE/VCO 2 slope, are among the strongest prognostic markers available. 6, 8 This assertion was confirmed in this study, demonstrating the VE/VCO 2 slope remained the single best predictor of adverse events over the entire 3-year period when all baseline variables listed in Table 1 were considered. Nevertheless, future investigations should determine whether the timedependent predictive trends for CPX variables in this study extend to other important clinical measures. Changes in the clinical management of the subjects included in this analysis during the follow-up period were not tracked. It is therefore possible that the addition of medications such as ␤-blockers or devices such as an implantable cardioverter defibrillator would alter prognosis and thus diminish the predictive ability of the CPX variables assessed. Previous research, however, has found that both peak VO 2 and the VE/VCO 2 slope remain prognostic irrespective of ␤-blocker use. 3, 6 In addition, analysis of the prognostic value of CPX has produced consistent results for Ͼ25 years, supporting the hypothesis that an abnormal CPX response portends a higher adverse event risk irrespective of treatment strategies. Finally, there is a referral bias that should be considered with respect to the characteristics of patients referred for CPX that likely differ from the overall HF population.
In conclusion, peak VO 2 and the VE/VCO 2 slope are wellestablished prognostic markers in patients with HF. Although this investigation affirms the overall prognostic strength of both peak VO 2 and the VE/VCO 2 slope, there seems to be a time constraint on their predictive utility, reflecting the variable nature of HF severity over time. Depending on the baseline CPX response, clinicians may want to consider repeating CPX over a 2-to 4-year time period to more accurately identify change in adverse event risk.
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